1 / 4

Larotrectinib: Against 17 Types of Solid Tumors With No Limit To Cancer Types

Larotrectinib (trade name Vitrakvi is the first targeted drug that does not distinguish the source of tumor for initial treatment in the world. Larotrectinib is used for treat solid tumors with Neurotrophic tropomyosin-related kinase (NTRK) gene fusion in adults and children.

sunnyfang1419
Download Presentation

Larotrectinib: Against 17 Types of Solid Tumors With No Limit To Cancer Types

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Huateng Pharma Larotrectinib: Against 17 Types of Solid Tumors With No Limit To Cancer https://en.huatengsci.com On November 26, 2018, FDA approved an anti-cancer drug larotrectinib (trade name Vitrakvi®), which is the first targeted drug that does not distinguish the source of tumor for initial treatment in the world. Larotrectinib is used for treat solid tumors with Neurotrophic tropomyosin-related kinase (NTRK) gene fusion in adults and children. Why this drug makes the medical community and patients so exciting? There are three main reasons. Firstly, no limit to cancer types. This means that no matter what kinds of cancer (tissue/cell/site), as long as there is NTRK fusion, it can be used for treat 17 types of cancers including breast cancer, colorectal cancer, lung cancer, and thyroid cancer both in adults and children. Although larotrectinib has showed to be effective in alleviating clinical symptoms in patients with 17 types of cancer, in fact, there are still very few patients suitable for this drug, which is related to the conditions of application of larotinib. The key to the use of larotrectinib is the mutation of NTRK gene fusion. The three subtypes that have been discovered are NTRK1, NTRK2 and NTRK3. According to the existing data, the mutation rate of NTRK gene in infant fibrosarcoma is >90%, and the mutation rate in other types of tumors is less than 10%, which is much lower in the applicable population compared with the "magic drug" PD-1.

  2. Huateng Pharma https://en.huatengsci.com At the same time, how to find the right patients is also a challenge. In order to know whether you can choose larotrectinib for treatment, you must do a genetic test firstly to determine whether there is a NTRK gene mutation. If so, then larotrectinib is likely to have a significant effect on the patients. The following figure shows the efficacy and response duration of larotrectinib in different solid tumors.

  3. Huateng Pharma https://en.huatengsci.com In addition, the performance of larotrectinib is quite consistent between adult and children patients. The ORR (Objective Response Rate) was 73% in adults and 92% in children. Secondly, the ORR is as high as 79%. In the latest study, out of 153 evaluable patients, the ORR was as high as 79% (121/153), the complete response rate (CR) reached to 16% (24/153), and the condition of other 19 patients (12 %) is stable. The clinical benefit rate is 91%. We must make it clear that "effective" does not mean "cured".The effective rate is also called "objective response rate". According to the evaluation of the effectiveness of tumor therapy, the effective rate = (complete response + partial response) number of patients/total number of cases ×100%. Therefore, 79% effective rate means that 79% of patients with NTRK gene mutation tumors who was treated with larotrectinib have significantly reduced tumor and the clinical symptoms were relieved. Thirdly, quick response and long duration. The magic of larotrectinib is that it works very quickly, and once it works, the relief is often unexpected. The data showed that the average onset time was only 1.84 months, and 73% of patients responded with a duration of more than 6 months.

  4. Huateng Pharma https://en.huatengsci.com Different from traditional anti-cancer drugs, the indications of larotrectinib are not differentiated by a certain type of cancer. Instead, it targets a gene mutation, namely NTRK mutation. For patients with NTRK gene mutation, larotrectinib has a good therapeutic effect. What's more worth mentioning is that about 40% of patients with NTRK gene fusion have no tumor growth or metastasis within one year after the start of medication. This is very rare. Figure source: The New England Journal Of Medicine Huateng Pharma, a professional manufacturer of pharmaceutical API and intermediates. We supply many kinds of anti-cancer drugs intermediates such as Carfilzomib intermediates, Palbociclib intermediates, Ribociclib intermediates, Elagolix intermediates and so on. We can also provide Larotrectinib intermediates CAS No.1919868-77-1, CAS No. 1218935-60-4, CAS No. 1363380-51-1 and CAS No. 100243-39-8 with high purity. Related Articles: Basic Information About Larotrectinib (Vitrakvi)

More Related